A phase II study of pembrolizumab combination with temozolomide as 1L treatment for Chinese metastatic acral melanoma patients

被引：0
|
作者：
Ding, Y. [1 ]
Xu, Y. [2 ]
Zhang, X. [1 ]
Chen, Y. [2 ]
机构：
[1] Sun Yat Sen Univ Canc Ctr, Dept Biotherapy, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[2] Fudan Univ, Dept Musculoskeletal Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1199
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1131P
引用
收藏
页码：S743 / S743
页数：1
相关论文
共 50 条
  • [41] A phase I study of high-dose calcitriol in combination with temozolomide for patients (Pts) with metastatic melanoma (MM)
    Pettijohn, Erin
    Rademaker, Alfred
    Martone, Brenda K.
    Poast, Erica
    Weitner, Bing Bing
    Eklund, John W.
    Kuzel, Timothy
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] SEQUENTIAL COMBINATION OF LOW DOSE CHEMO-MODULATING TEMOZOLOMIDE WITH FOTEMUSTINE IN METASTATIC MELANOMA (MM). A PHASE II STUDY
    Guida, M.
    Cramarossa, A.
    Petrillo, P.
    Albano, A.
    Pisconti, S.
    Aieta, M.
    Traversa, M.
    Ridolfi, R.
    Colucci, G.
    ANNALS OF ONCOLOGY, 2012, 23 : 370 - 370
  • [43] ENCORE 601: A phase II study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with melanoma.
    Johnson, Melissa Lynne
    Gonzalez, Rene
    Opyrchal, Mateusz
    Gabrilovich, Dmitry
    Ordentlich, Peter
    Brouwer, Susan
    Sankoh, Serap
    Schmidt, Emmett V.
    Meyers, Michael L.
    Agarwala, Sanjiv S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [44] Phase II Study of Pembrolizumab and Itacitinib for First Line Treatment of Metastatic NSCLC Expressing PD-L1
    Marmarelis, M. E.
    Mathew, D.
    Bauml, J. M.
    Hwang, W. -T.
    Zhang, J.
    Singh, A.
    D'Avella, C.
    Davis, C.
    Ye, D.
    Sun, L.
    Ciunci, C.
    Zhang, N.
    Aggarwal, C.
    Cohen, R. B.
    Minn, A. J.
    Wherry, E. J.
    Langer, C. J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S122 - S123
  • [45] Temozolomide and thalidomide in the treatment of advanced melanoma, a phase II study.
    Okeke, IR
    Laber, DA
    Bev, T
    McMasters, KM
    Miller, DM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 728S - 728S
  • [46] A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients
    Benjamin Weide
    Thomas Eigentler
    Chiara Catania
    Paolo Antonio Ascierto
    Stefano Cascinu
    Jürgen C. Becker
    Axel Hauschild
    Antonella Romanini
    Riccardo Danielli
    Reinhard Dummer
    Uwe Trefzer
    Giuliano Elia
    Dario Neri
    Claus Garbe
    Cancer Immunology, Immunotherapy, 2019, 68 : 1547 - 1559
  • [47] A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients
    Weide, Benjamin
    Eigentler, Thomas
    Catania, Chiara
    Ascierto, Paolo Antonio
    Cascinu, Stefano
    Becker, Juergen C.
    Hauschild, Axel
    Romanini, Antonella
    Danielli, Riccardo
    Dummer, Reinhard
    Trefzer, Uwe
    Elia, Giuliano
    Neri, Dario
    Garbe, Claus
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (09) : 1547 - 1559
  • [48] Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
    Middleton, MR
    Grob, JJ
    Aaronson, N
    Fierlbeck, G
    Tilgen, W
    Seiter, S
    Gore, M
    Aamdal, S
    Cebon, J
    Coates, A
    Dreno, B
    Henz, M
    Schadendorf, D
    Kapp, A
    Weiss, J
    Fraass, U
    Statkevich, P
    Muller, M
    Thatcher, N
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) : 158 - 166
  • [49] Phase II study of extended-dose temozolomide in patients with melanoma
    Rietschel, Petra
    Wolchok, Jedd D.
    Krown, Susan
    Gerst, Scott
    Jungbluth, Achim A.
    Busam, Klaus
    Smith, Katherine
    Orlow, Irene
    Panageas, Katherine
    Chapman, Paul B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (14) : 2299 - 2304
  • [50] A phase II study of gefitinib in patients with metastatic melanoma
    Patel, S.
    Bedikian, A.
    Kim, K.
    Papadopoulos, N.
    Hwu, P.
    Vardeleon, A.
    Prieto, V.
    Bar Eli, M.
    Bronstein, Y.
    Bassett, R., Jr.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345